Advanced Biomedical Technologies (ABMT) stock price, revenue, and financials

Advanced Biomedical Technologies market cap is $11.7 m, and annual revenue was $123.59 k in FY 2020
View Company

$11.7 M

ABMT Mkt cap, 05-Feb-2021

$123.6 K

Advanced Biomedical Technologies Revenue FY, 2020
Advanced Biomedical Technologies Gross profit (FY, 2020)71.8 K
Advanced Biomedical Technologies Gross profit margin (FY, 2020), %58.1%
Advanced Biomedical Technologies Net income (FY, 2020)-672 K
Advanced Biomedical Technologies EBIT (FY, 2020)-446.6 K
Advanced Biomedical Technologies Cash, 31-Oct-2020201.7 K
Advanced Biomedical Technologies EV11.6 M

Advanced Biomedical Technologies Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

11.7k123.6k

Cost of goods sold

7.6k51.8k

Gross profit

4.1k71.8k

Gross profit Margin, %

35%58%

R&D expense

47.7k60.2k57.3k48.1k56.5k263.6k183.0k

General and administrative expense

543.4k514.5k374.4k342.0k561.2k324.0k224.5k

Operating expense total

801.1k832.4k695.1k678.0k937.0k608.8k518.4k

Depreciation and amortization

26.6k30.5k29.6k13.6k16.3k21.2k17.0k

EBIT

(827.8k)(605.2k)(461.3k)(403.6k)(634.0k)(604.7k)(446.6k)

EBIT margin, %

(5188%)(361%)

Interest expense

36.036.024.044.0

Interest income

137.0119.059.036.036.024.044.0

Pre tax profit

(862.9k)(724.7k)(691.6k)(953.3k)(948.8k)(672.0k)

Income tax expense

Net Income

(827.8k)(862.9k)(724.7k)(691.6k)(953.3k)(948.8k)(672.0k)

Quarterly

USDQ3, 2011Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

60.5k(211.0)

Cost of goods sold

33.1k

Gross profit

27.4k

Gross profit Margin, %

45%

R&D expense

12.5k43.2k19.4k3.4k5.4k10.4k9.4k19.9k23.2k1.1k28.8k35.4k17.1k21.8k14.3k13.0k7.8k15.8k8.0k13.2k17.0k16.0k48.1k56.8k41.3k

General and administrative expense

158.4k111.4k110.7k109.1k88.0k101.3k133.2k117.9k131.6k134.1k145.5k107.4k80.9k124.9k79.0k69.6k100.2k74.3k121.7k118.3k120.8k147.9k127.5k71.1k54.3k57.8k

Operating expense total

180.7k153.6k184.3k168.8k132.1k149.9k192.6k178.1k204.9k216.7k209.7k202.7k182.8k207.7k166.2k149.4k179.7k165.4k220.4k206.5k213.6k247.5k230.7k119.2k127.0k120.2k

Depreciation and amortization

6.7k6.7k6.6k6.6k7.9k8.0k7.7k7.7k7.4k4.7k3.6k4.6k2.2k2.3k2.3k5.0k5.0k6.2k5.1k3.9k

EBIT

(166.8k)(130.5k)(160.5k)(135.0k)(97.8k)(113.2k)(150.3k)(134.0k)(158.2k)(163.9k)(154.5k)(144.2k)(124.1k)(149.7k)(108.3k)(88.6k)(116.8k)(86.8k)(139.6k)(128.6k)(136.2k)(169.9k)(148.5k)(125.4k)(99.6k)(120.3k)

EBIT margin, %

(165%)57030%

Interest expense

22.9k24.6k10.087.4k5.0

Interest income

24.024.040.020.015.017.024.039.038.034.0558.0131.012.010.025.010.06.015.07.014.06.010.07.04.05.05.0

Pre tax profit

(223.3k)(217.7k)(210.7k)(190.5k)(215.4k)(173.6k)(154.1k)(183.3k)(170.0k)(222.5k)(208.8k)(215.8k)(252.5k)(235.7k)(212.9k)(63.8k)(209.7k)

Income tax expense

Net Income

(189.1k)(160.1k)(190.9k)(175.3k)(138.6k)(156.5k)(199.3k)(184.8k)(211.5k)(223.3k)(217.7k)(210.7k)(190.5k)(215.4k)(173.6k)(154.1k)(183.3k)(170.0k)(222.5k)(208.8k)(215.8k)(252.5k)(235.7k)(212.9k)(63.8k)(209.7k)

Advanced Biomedical Technologies Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

74.4k38.3k6.6k7.5k6.9k5.6k201.7k

Prepaid Expenses

18.8k18.1k20.5k17.5k32.6k49.8k29.3k

Inventories

2.8k64.1k100.0k

Current Assets

93.1k59.2k27.0k24.9k39.5k119.5k331.0k

PP&E

108.3k106.6k72.5k60.5k102.9k99.0k105.5k

Total Assets

217.6k165.8k100.7k85.4k142.4k218.5k469.2k

Short-term debt

28.0k

Current Liabilities

4.0m4.6m4.5m5.1m5.8m6.7m7.9m

Long-term debt

7.0k

Total Debt

35.1k

Common Stock

569.0569.0671.0694.0696.0698.0702.0

Additional Paid-in Capital

1.9m1.9m2.5m2.7m2.7m2.8m2.8m

Retained Earnings

(5.4m)(6.3m)(7.0m)(7.7m)(8.6m)(9.6m)(10.3m)

Total Equity

(3.7m)(4.5m)(4.4m)(5.0m)(5.6m)(6.5m)(7.4m)

Financial Leverage

-0.1 x0 x0 x0 x0 x0 x-0.1 x

Quarterly

USDQ3, 2011Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

75.8k64.8k43.4k44.5k31.7k38.0k54.8k57.0k54.4k47.0k102.3k58.6k18.2k22.8k8.9k7.0k35.9k9.6k18.8k13.5k16.0k16.9k11.9k10.9k8.1k10.6k

Prepaid Expenses

22.1k20.7k20.5k23.6k21.4k22.7k22.7k24.2k31.3k31.6k19.0k24.4k28.5k25.6k25.5k21.5k19.2k20.2k20.3k18.9k44.9k47.5k50.2k59.9k36.4k

Inventories

14.1k35.7k49.4k64.5k

Current Assets

98.8k86.9k64.1k65.0k55.3k59.4k77.5k79.7k78.6k78.3k187.3k77.6k49.8k51.4k34.4k32.6k57.4k28.8k39.0k33.8k34.8k61.9k73.5k96.8k117.4k111.6k

PP&E

64.4k147.9k141.9k137.1k131.7k128.5k128.3k118.1k113.5k128.7k121.8k116.5k94.9k90.0k80.8k66.7k63.0k59.8k66.2k64.1k69.4k110.2k108.5k100.2k96.0k112.3k

Total Assets

178.2k235.1k207.6k203.7k187.0k188.4k205.7k198.2k192.1k209.7k312.0k194.1k146.0k142.6k116.5k99.3k120.3k88.7k105.2k129.4k131.0k189.6k199.3k218.5k277.9k276.4k

Short-term debt

45.3k42.3k

Current Liabilities

1.5m1.6m1.7m2.6m2.7m2.9m3.4m3.4m3.7m4.1m4.4m4.5m4.2m4.4m4.4m4.6m4.6m4.8m5.6m5.8m5.6m6.3m6.5m6.6m6.9m7.0m

Long-term debt

22.3k13.1k

Total Debt

67.6k55.4k

Total Liabilities

2.1m2.2m2.6m

Common Stock

566.0566.0566.0566.0566.0569.0569.0569.0569.0569.0569.0669.0671.0671.0671.0694.0694.0694.0694.0694.0696.0696.0696.0698.0700.0

Additional Paid-in Capital

1.6m1.7m1.7m1.7m1.7m1.7m1.9m1.9m1.9m1.9m1.9m1.9m2.5m2.5m2.5m2.5m2.7m2.7m2.7m2.7m2.7m2.7m2.7m2.7m2.8m2.8m

Retained Earnings

(1.4m)(5.8m)(6.1m)(6.5m)(6.7m)(6.8m)(7.1m)(7.3m)(7.5m)(7.9m)(8.1m)(8.3m)(8.9m)(9.1m)(9.3m)(9.6m)(9.9m)

Total Equity

(1.4m)(1.9m)(2.0m)(2.4m)(2.6m)(2.7m)(3.1m)(3.2m)(3.5m)(3.9m)(4.1m)(4.3m)(4.0m)(4.2m)(4.3m)(4.5m)(4.5m)(4.8m)(5.5m)(5.6m)(5.5m)(6.1m)(6.3m)(6.4m)(6.6m)(6.7m)

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0.2 x

Financial Leverage

-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Advanced Biomedical Technologies Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(827.8k)(862.9k)(724.7k)(691.6k)(953.3k)(948.8k)(672.0k)

Depreciation and Amortization

26.6k30.5k29.6k13.6k16.3k21.2k17.0k

Inventories

(2.8k)2.7k(65.5k)(31.3k)

Accounts Payable

(6.4k)252.8k63.9k54.9k240.0k1.2m

Cash From Operating Activities

(732.4k)(820.4k)(371.7k)(557.7k)(832.4k)(742.5k)646.7k

Purchases of PP&E

(8.8k)(32.3k)(1.7k)(453.0)(64.4k)(18.6k)(30.7k)

Capital Expenditures

(15.0k)

Cash From Investing Activities

(23.8k)(16.4k)(3.0k)760.0(64.4k)(18.6k)(30.7k)

Cash From Financing Activities

782.2k802.0k343.8k557.8k896.3k759.8k(427.8k)

Net Change in Cash

26.0k(36.0k)(31.7k)904.0(603.0)(1.3k)196.1k

Interest Paid

36.036.024.044.0

Free Cash Flow

(747.4k)

Quarterly

USDQ3, 2011Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(189.1k)(160.1k)(550.4k)(175.3k)(313.8k)(470.4k)(199.3k)(384.1k)(595.6k)(223.3k)(441.0k)(651.7k)(190.5k)(405.9k)(579.6k)(154.1k)(337.4k)(507.5k)(222.5k)(431.4k)(647.2k)(252.5k)(488.2k)(701.1k)(63.8k)(273.4k)

Depreciation and Amortization

1.3k6.5k18.4k6.4k12.9k19.5k6.7k13.4k20.0k6.6k14.6k22.6k7.7k15.4k22.8k4.7k8.3k12.9k2.2k6.3k11.3k5.0k10.0k16.2k5.1k9.1k

Inventories

2.7k2.7k2.7k(14.0k)(36.1k)15.7k(627.0)

Accounts Payable

4.4k(15.5k)(17.1k)(501.0)226.8k226.6k17.0k94.3k112.3k(9.6k)13.1k24.6k55.6k71.4k178.4k(15.2k)2.0k

Cash From Operating Activities

(156.5k)(307.5k)(438.6k)(168.5k)(365.0k)(563.2k)(220.6k)(445.1k)(630.9k)(182.4k)(109.2k)(268.6k)(133.7k)(190.7k)(331.6k)(228.3k)(406.5k)(601.7k)(199.8k)(428.0k)(550.0k)(51.9k)(206.9k)

Purchases of PP&E

(1.5k)(1.5k)(4.1k)(6.5k)(8.1k)(8.4k)(29.7k)(29.6k)(32.5k)(1.3k)(1.7k)(4.5k)(5.3k)(17.7k)(8.0k)(12.1k)(12.4k)(525.0)(28.3k)

Capital Expenditures

1.2k836.01.1k13.4k13.1k16.0k(17.3k)(21.6k)

Cash From Investing Activities

(49.4k)(1.5k)(1.5k)(3.0k)(6.5k)(7.3k)(7.3k)(16.3k)(16.5k)(16.5k)(1.3k)(2.6k)(3.0k)1.2k1.2k1.2k(4.5k)(38.1k)(50.4k)(25.0k)(29.4k)(34.0k)(525.0)(28.3k)

Cash From Financing Activities

429.6k153.4k291.5k430.0k181.2k382.1k576.9k210.4k490.2k632.3k164.3k96.9k243.0k133.0k218.9k333.4k243.5k450.4k660.9k234.6k462.3k588.1k54.8k240.3k

Net Change in Cash

(35.3k)(4.6k)(17.3k)(11.1k)6.4k8.6k6.0k(27.3k)27.9k(15.8k)(20.1k)(15.5k)(29.4k)471.029.3k3.1k11.3k6.0k8.5k10.1k5.0k4.0k2.5k5.0k

Interest Paid

(22.9k)(67.3k)10.017.021.05.010.0

Free Cash Flow

(439.7k)(365.9k)(564.3k)(234.1k)(458.2k)(646.9k)(445.3k)(571.6k)

Advanced Biomedical Technologies Ratios

USDQ3, 2011

Financial Leverage

-0.1 x
View Advanced Biomedical Technologies profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more